Navigation Links
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Date:8/19/2007

product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease. Both products are being developed in partnership with Merck Serono, a division of Merck KgA of Darmstadt, Germany. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its product candidate Kuvan; expectations regarding the Kuvan expanded access program; expectations regarding filings with regulatory agencies; and the development of 6R-BH4 for other indications. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of ongoing clinical trials related to Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities concerning Kuvan; results and timing of current and planned clinical trials of 6R-BH4 for other indications; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual R
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, today announced ... year 2014 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... by Dan Myers , President and Chief Executive ...
(Date:7/24/2014)... , July 24, 2014  The American ... is supporting its mission to help address audit ... and exclusive agreement to be the information technology ... As the leading provider of billing and business ... unmatched HME industry expertise to support this important ...
(Date:7/24/2014)... , July 24, 2014  In any given hospital ... 25 patients has at least one hospital-acquired infection, according ... more, many of these infections prove fatal. And as ... alarming number of patient deaths per year, infection control ... Consequently, a stronger emphasis is being ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3
... Computer Company (PCC) – a Vermont pediatric software developer ... updated 5010 transaction standard for electronic claims and claims ... among its payers. An ICD-10/5010 Readiness Survey ... Systems Society (HIMSS), indicates an estimated 1/3 of health ...
... Masimo (NASDAQ: MASI ) announced today that it ... 2, 2011, after the market closes on May 3, 2011. ... 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by ... Raad, Executive Vice President and Chief Financial Officer. A ...
Cached Medicine Technology:PCC Frustrated with Payers' Lack of 5010 Readiness 2Masimo to Report First Quarter 2011 Financial Results After Market Close on May 3, 2011 2Masimo to Report First Quarter 2011 Financial Results After Market Close on May 3, 2011 3
(Date:7/25/2014)... Washington, DC (PRWEB) July 25, 2014 ... against some health plans for providing inadequate access to ... serious threats to the health and safety of beneficiaries ... of drug coverage determinations, and CMS is taking quick ... 5, the Atlantic Information Services webinar, “Avoiding Costly ...
(Date:7/25/2014)... iTanSmart is a patented iOS suntan ... provides a tailored approach to eliminating the guesswork from ... skin damage. In his review, Eaton had positive things ... iTanSmart. , Eaton begins his commentary ... organized’ and ‘great alternative’ to its related Android competitor. ...
(Date:7/25/2014)... As the category creator and world leader in healthy ... transform and improve individual lives worldwide through its exclusive and ... a successful Austin, Texas based "Xocai Activ Drink" author, is ... July to promote the up and coming mxicorp.com/company/igc Eric Worre ... has been a leader in the Network Marketing Profession for ...
(Date:7/24/2014)... iFitDress.com, a renowned wedding dress manufacturer ... casual party dresses . According to the company’s ... now offered at discounted prices, up to 59% off. ... August 04. , Most of the casual party ... market. They are popular for special designs, delicate craftsmanship ...
(Date:7/24/2014)... For rats bearing human breast tumors, exposure to ... the breast cancer drug tamoxifen, according to data published ... American Association for Cancer Research. The negative effects of ... giving rats a melatonin supplement during the night. , ... with hormone receptor-positive breast cancer," said Steven M. Hill, ...
Breaking Medicine News(10 mins):Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2
... new analysis, it is better to give radiation therapy before ... well as surgery can reduce the risk of recurrence. Generally ... In Scandinavia and the Netherlands, the therapy is given before ... until afterwards.// ,An analysis of 8000 patients, led ...
... The diagnosis and treatment of epilepsy is often handled ... per cent of UK epilepsy patients not receiving appropriate ... epilepsy each year, and of these, about one-third can ... from the Institute of Neurology at University College London ...
... temperatures can lead to heat exhaustion and eventually to ... the temperature rises into the thirties. By the time ... ,Heat exhaustion refers to overheating of the ... rare cases, salt depletion. People who suffer from heat ...
... by cancer patients undergoing high-dose chemotherapy could be eased ... drugs used to fight cancer can prove extremely debilitating ... various anti-emetic drugs to lessen the reaction, but in ... a possible extra help. ,Acupuncture involves the insertion of ...
... Patients' experience of illness is being collected on a database ... ingredient in medical research is the patient's voice. It is ... researchers could learn a lot from the patient's ideas, beliefs ... too - showing they're not alone, and giving them vital ...
... able to treat the neurological problems that are common ... suffer from kidney failure, which is usually caused by ... leads to neurological complications like fatigue, apathy, emotional instability ... at the University of California at Irvine have learned ...
Cached Medicine News:
... The Bledsoe Lever Lock Knee Brace ... extension lock of the arthroscopic ACL ... allow motion for rehabilitation or passive ... locked "rigidly" in full extension for ...
The Bledsoe Basic Knee Brace offers a broad range of features that are unmatched by any other brace in its price range. Application of this brace is the easiest of any brace on the market....
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....
Medicine Products: